Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Pooja KhandelwalKasiani C Myers

Abstract

We describe our retrospective clinical experience with ruxolitinib for steroid-refractory acute graft-versus-host disease (GVHD) in pediatric allogeneic hematopoietic stem cell transplant (HSCT) patients. Ruxolitinib was administered orally at 5 mg twice daily for children ≥ 25 kg or 2.5 mg twice daily if <25 kg. We excluded patients who received new immune suppressive agents within 2 weeks before initiation of ruxolitinib from response analysis. Patients were called a treatment failure if ruxolitinib was stopped before completion of 4 weeks of therapy because of adverse effects and not because of progression of acute GVHD. Thirteen patients received ruxolitinib, and 11 patients were assessable for response. One patient achieved a complete response, 4 had a partial response, and 2 had no response at 4 weeks after the first ruxolitinib dose. Four patients were treatment failures. Overall response rate was 45%. Adverse effects (n = 13) included grades 3 to 4 elevated alanine transaminase (n = 7), grades 3 to 4 neutropenia (n = 5), and grade 4 thrombocytopenia (n = 3). Infectious complications in patients included for response analysis (n = 11) were Epstein-Barr viremia (n = 2), adenovirus (n = 2), BK (n = 3), bacterial infections...Continue Reading

References

Citations

Mar 29, 2018·Expert Review of Clinical Immunology·Alexandra Laberko, Andrew R Gennery
Jun 8, 2018·Current Opinion in Pediatrics·Trisha Bhat, Carrie C Coughlin
Oct 12, 2018·Proteomics. Clinical Applications·Sophie Paczesny, Jochen Metzger
Sep 13, 2018·Pediatric Blood & Cancer·Marta Gonzalez VicentMiguel A Diaz
Feb 18, 2020·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Julien ZuberRémi Salomon
Mar 11, 2020·Expert Review of Clinical Immunology·Haris AliRyotaro Nakamura
Aug 19, 2020·Journal of the Pediatric Infectious Diseases Society·Daniel E DulekHamid Bassiri
Jun 7, 2018·Bone Marrow Transplantation·Helene M SchoemansEBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (Natio
Jun 28, 2018·Frontiers in Cell and Developmental Biology·Elizabeth A ComenMaria Kleppe
Apr 9, 2019·BioMed Research International·Thomas NeumannWilliam Krüger
Dec 8, 2017·Experimental Hematology & Oncology·Mauricio Sarmiento MaldonadoJose Antonio Perez-Simón
Jan 5, 2018·Expert Review of Clinical Immunology·Mary A Slatter, Andrew R Gennery
Apr 4, 2020·Leukemia·Florent MalardJoycelyn P Y Sim
Dec 4, 2019·Frontiers in Oncology·Elena Maria ElliGiuseppe Alberto Palumbo
Apr 12, 2019·Bone Marrow Transplantation·Elizabeth A de KortWalter J F M van der Velden
Jun 6, 2018·Frontiers in Immunology·Lingling ZhangWei Wei
Sep 14, 2018·Therapeutic Advances in Hematology·Michael ByrneMichael R Savona
Sep 27, 2020·International Journal of Hematology·Rintaro OnoDaisuke Hasegawa
Dec 28, 2019·Annals of Hematology·Guangqiang MengZhao Wang
Jul 31, 2020·Clinical Lymphoma, Myeloma & Leukemia·Francine M FossSheela V Shenoi

Related Concepts

INCA24
Teens
Graft-vs-Host Disease
Pyrazoles
Salvage Therapy
Hemopoietic Stem Cell Transplant
Transplantation Conditioning
Adenoviruses
Alanine Transaminase
Bacterial Infections

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.